Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2430-2435

  Tsaur, Igor ^a   Karalis, Athanasios ^a   Probst, Michael ^a   Blaheta, Roman A ^a   Scheuermann, Ernst Heinrich ^b,c   Gossmann, Jan ^c,d   Kachel, Heinz Georg ^c   Hauser, Ingeborg A ^b   Jonas, Dietger ^a   Obermüller, Nicholas ^b  

^a Departments of Urology and Pediatric Urology   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c KFH Kidney Center   (Germany)

^d Dialysis Center Darmstadt/Dieburg/Langen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTATE SPECIFIC ANTIGEN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANALGESIC NEPHROPATHY; ARTICLE; BALKAN ENDEMIC NEPHROPATHY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC GLOMERULONEPHRITIS; CHRONIC PYELONEPHRITIS; CLINICAL ASSESSMENT; CONGENITAL MEGAURETER; CONGENITAL RENAL DYSPLASIA; DEATH; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GERM CELL TUMOR; GLOMERULONEPHRITIS; GRAFT RECIPIENT; GRAFT REJECTION; HEALTH CARE FACILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY DYSPLASIA; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROSCLEROSIS; OVERALL SURVIVAL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPSIS; SKIN CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TUMOR LOCALIZATION; UREMIA; URETER DISEASE; URIC ACID NEPHROPATHY; URINARY TRACT CANCER; VESICOURETERAL REFLUX; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS; YOUNG ADULT;

EID: 77958521880     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01676.x     Document Type: Article

References (35)

1. García-Prado ME, Cordero E, Cabello V et al. Infectious complications in 159 consecutive kidney transplant recipients. Enferm Infecc Microbiol Clin 2009; 27: 22-27.
2. Sagedal S, Hartmann A, Nordal K et al. Impact of early cytomegalovirus infection and disease on longterm recipient and kidney graft survival. Kidney Int 2004; 66: 329-337.
3. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008; 3(Suppl 2): 68-75.
4. Nampoory MR, Khan ZU, Johny KV et al. Invasive fungal infections in renal transplant recipients. J Infect 1996; 33: 95-101.
5. Hagen M, Hjelmsaeth J, Jenssen T, Morkrid L, Hartmann A. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 2154-2159.
6. Akgul A, Sasak G, Basaran C, Colak T, Ozdemir FN, Haberal M. Relationship of renal resistive index and cardiovascular disease in renal transplant recipients. Transplant Proc 2009; 41: 2835-2837.
7. Veroux M, Puliatti C, Fiamingo P et al. Early de novo malignancies after kidney transplantation. Transplant Proc 2004; 36: 718-20.
8. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-31.
9. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-13.
10. Maluccio M, Sharma V. Tacrolimus enhances transforming growth factor-beta 1 expression and promotes tumor progression. Transplantation 2003; 76: 597-602.
11. Hojo M, Morimoto T, Maluccio et al Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 377: 530-4.
12. Nguyen T, Vacek PM, O'Neill P, Colletti RB, Finette BA. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res 2009; 69: 7004-12.
13. Koukourgianni F, Harambat J, Ranchin B et al. Malignancy incidence after renal transplantation in children: a 20-year single centre experience. Nephrol Dial Transplant 2010; 25: 611-6.
14. Stewart JH, Buccianti G, Agodoa L et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe and Australia and New Zealand. J Am Soc Nephrol 2003; 14: 197-207.
15. Maisonneuve P, Agoada L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-9.
16. Wimmer CD, Rentsch M, Crispin A et al. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the transplantation Center Munich. Kidney Int 2007; 71: 1271-1278.
17. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80(Suppl 2): S254-64.
18. Kapoor A. Malignancy in kidney transplant recipients. Drugs 2008; 68(Suppl 1): 11-9.
19. Chapman JR, Webster AC. Cancer after renal transplantation: the next challenge. Am J Transplant 2004; 4: 841-842.
20. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15-183 recipients. Am J Transplant 2007; 7: 2140-2151.
21. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and and infection. Drugs 2009; 69: 2227-43.
22. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 147-58.
23. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term transplants. Transplantation 1995; 59: 1705-9.
24. Besarani D, Cranston D. Urological malignancy after renal transplantation. BJU Int 2007; 100: 502-505.
25. Muruve NA, Shokes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005; 80: 709-716.
26. Davison AM. Epidemiology of cancer in patients with renal transplants. Adv Nephrol Necker Hosp 1998; 28: 171-94.
27. Elkentaoui H, Robert G, Pasticier G et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French department of Urology and kidney transplantation from Bordeaux. Urology 2010; 75: 126-132.
28. Doublet JD, Peraldi MN, Gattegno B, Thibault P, Sraer JD. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997; 158: 42-44.
29. Neuzillet Y, Lay F, Luccioni A et al. De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer 2005; 103: 251-257.
30. Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology 1997; 50: 525-528.
31. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1-155.
32. Kälble T, Alcaraz A, Budde K et al. Guidelines on renal transplantation. European Association of Urology, 2009. Available from URL: .
33. Tillou X, Demailly M, Hakami F, Westeel PF, Saint F, Petit J. De novo renal carcinoma in renal transplant recipients: effect of early treatment. Transplant Proc 2009; 41: 3314-3316.
34. Filocamo MT, Zanazzi M, Li Marzi V et al. Renal cell carcinoma of native kidney after renal transplantation: clinical relevance of early detection. Transplant Proc 2009; 41: 4197-4201.
35. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-586.